Non-small cell lung cancer
Conditions
Interventions
A:Platinum-based two bites MDT
B:Single-acemotherapy combined compound Kuhshen Injectiongent
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Before the start of the study, All patients have been fully understood and the willingness to sign the informed consent; (2) Aged from 60 to 75 years old,Sex unlimited; (3) III-IV stage NSCLC must be diagnosis by pathology; (4) According to RECIST, At least 1 Measurable lesions without local treatment, Spiral CT or MRI, maximum diameter larger than at least 10mm (Malignant lymph nodes on CT scans short diameter larger than at least 15mm); (5) Eastern Cooperative Oncology Group (ECOG) performance status less than at least 2; (6) The basic normal organ function, WBC more than 3.0*10^9/L; NEUT# more than 1.5*10^9/L; PLT more than 60*10^9/L; HGB more than 8.0g/dl; BIL at normal level or less than 1.5*ULN; AST(SGOT), ALT(SGPT) less than 2.0*ULN); SCr less than 1.5*ULN; (7) Expected survival time must more than 3 months.
Exclusion criteria
Exclusion criteria: (1) Ever received compound Kushen therapy within 2 weeks; (2) Pregnancy or lactation women; (3) Only with immeasurable lesions such as pleural effusion,pulmonary lymphangitic carcinomatosis, ascites, peritoneal cancer lesions, diffuse hepatic involvement, bone metastasis; (4) Patients with severe, uncontrolled organic lesions or infection, such as decompensated heart, lung, kidney failure can lead to tolerance of chemotherapy; (5) participating in another clinical study or have participated in another clinical study within 30 days; (6) Aallergic to the testing compound.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease control rates;Objective response rate;Progression-free surial; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Quality of Life;Clinical Symptoms;Tumor markers;weight;Adverse reactions;ECOG PS; | — |
Countries
China
Contacts
Public ContactHongsheng Lin
Outcome results
None listed